This study investigates the immune profile of patients receiving treatment with venetoclax plus azacitidine for acute myeloid leukemia (AML). Studying the information gathered from the immune profile from blood and bone marrow samples may help researchers understand the associated responses to the treatment of patients undergoing therapy of venetoclax plus azacitidine and create future immune based treatment approaches.
Acute Myeloid Leukemia
This study investigates the immune profile of patients receiving treatment with venetoclax plus azacitidine for acute myeloid leukemia (AML). Studying the information gathered from the immune profile from blood and bone marrow samples may help researchers understand the associated responses to the treatment of patients undergoing therapy of venetoclax plus azacitidine and create future immune based treatment approaches.
Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy
-
Mayo Clinic in Arizona, Scottsdale, Arizona, United States, 85259
Mayo Clinic in Florida, Jacksonville, Florida, United States, 32224-9980
Mayo Clinic in Rochester, Rochester, Minnesota, United States, 55905
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Mayo Clinic,
Talha Badar, M.D., PRINCIPAL_INVESTIGATOR, Mayo Clinic
2026-12-31